Retatrutide (research code LY3437943) is an experimental peptide and a triple receptor agonist of the GIP, GLP-1 and glucagon receptors. One of the most common questions about this compound is not about its mechanism but about its dosage and titration schedule: what doses were studied, how the dose was escalated week by week, and why researchers did not start at the target level. This article pulls together the published phase 1b, 2 and 3 protocols to show how retatrutide was dosed in controlled trials. The scientific background of the compound is covered in depth in our retatrutide monograph.
A framing note up front: every dose, interval and result below is taken from peer-reviewed clinical trials and is provided strictly as reference material for research purposes. It is not a directions-for-use document and not medical advice. Retatrutide and the other compounds on this site are supplied for laboratory research only and are not intended for human consumption.
Why retatrutide is titrated instead of started at the target dose
The most frequent adverse events across every retatrutide trial are gastrointestinal (nausea, diarrhoea, vomiting, constipation), and they are clearly dose-dependent: more common at higher doses and with faster escalation. That is why the phase 2 program did not give the target dose from week one but reached it stepwise, starting at a low dose and raising it at a fixed interval. The point of titration is to let the body and gut adapt so that tolerability is better once the maintenance (target) dose is reached [1][2].
Investigators even tested whether titration speed matters: in phase 2, some target doses were reached by two paths, starting from a lower or a higher initial dose. This allowed a slower and a faster approach to the same maintenance dose to be compared [1].
The pharmacokinetics behind the weekly schedule
Retatrutide is a large molecule (≈4731 Da) given subcutaneously once weekly. That interval is not arbitrary: the compound's half-life is approximately 6 days (reported as 5–7 days), and time to peak concentration in multiple-ascending-dose work is about 12–48 hours [3][4]. A long half-life means concentrations change slowly, so each fixed weekly titration step only reaches a steady level several weeks after the increase, another reason not to rush escalation.
What the phase 2 obesity trial showed (Jastreboff, 2023)
In a randomised phase 2 obesity trial, retatrutide produced pronounced, dose-dependent weight loss versus placebo over 48 weeks [1]. It was one of the largest effects shown in this class at the time, and it was the results, not the administration schedule, that put the molecule on the map. We do not give the specific titration protocol or the weekly doses here as instruction: they are collected in the reference Retatrutide: dosing schedule.
Where the weekly schedule came from: phase 1b (Urva, 2022)
Before the phase 2 trials, a phase 1b multiple-ascending-dose study in people with type 2 diabetes characterized the compound's pharmacology and confirmed the feasibility of once-weekly subcutaneous administration with gradual titration. It was this data that set the dosing interval and starting doses later scaled up in phase 2 [3]. The discovery of the molecule and its preclinical and early clinical profile are described by Coskun et al. [4].
What phase 3 added
Phase 3 results began to appear in 2026. The TRANSCEND-T2D-1 trial evaluated the efficacy and safety of retatrutide in people with type 2 diabetes on a background of diet and exercise [6]. Phase 3 data matter because they test the dose-dependent phase 2 findings in larger, longer cohorts, exactly the confirmation the early program lacked.
Tolerability and why titration speed matters
In both phase 2 trials gastrointestinal events were the most common, mostly mild to moderate and dose-dependent: in the diabetes trial the frequency ranged from roughly 13% at the lowest doses to about 50% at the highest [1][2]. A dose-dependent rise in heart rate was also seen, peaking around week 24 and then declining [1]. The slower versus faster approach to the target dose existed precisely to assess how the speed of reaching the target dose affects tolerability, which is why the slower start was used for the highest target doses.
From dose to solution: the reconstitution context
Study doses (in milligrams per week) are mapped in the lab to a solution volume. Retatrutide is supplied as a lyophilized powder in 5, 10, 20 and 60 mg vials; before use it is reconstituted with bacteriostatic water. Stock concentration = vial mass / added water volume. For example, a 10 mg vial reconstituted with 2 mL of water gives 5 mg/mL, so a 2 mg aliquot corresponds to 0.4 mL of solution. We walk through this calculation step by step in the guide on how to reconstitute peptides with bacteriostatic water. This is a purely computational, laboratory context, not a use recommendation.
How it compares with other incretin compounds
The "start low, double every 4 weeks" pattern echoes the approach used for other incretins, but the target doses and the number of receptor arms differ. How retatrutide compares with semaglutide and tirzepatide on mechanism and data is covered separately in semaglutide vs tirzepatide vs retatrutide.
Disclaimer: research use only
This material is compiled from publicly available peer-reviewed sources and provided for reference purposes only. It is not medical advice or a use recommendation. Retatrutide is an experimental compound that is not an approved medicine; any products mentioned are supplied for laboratory research purposes only and are not intended for human consumption, diagnosis or treatment. All doses and results above were obtained under controlled trial conditions and cannot be interpreted as directions for use.
The full list of sources with links, is in the monograph: Retatrutide.
